Barry Ticho Sells 4,767 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 4,767 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $152,687.01. Following the transaction, the insider directly owned 25,655 shares in the company, valued at approximately $821,729.65. The trade was a 15.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Barry Ticho also recently made the following trade(s):

• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.04, for a total value of $208,391.04.
• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10.

Stoke Therapeutics Price Performance

Shares of STOK opened at $33.03 on Thursday. The company’s fifty day moving average price is $30.90 and its 200-day moving average price is $32.23. Stoke Therapeutics, Inc. has a 1-year low of $18.00 and a 1-year high of $40.22. The firm has a market capitalization of $2.13 billion, a PE ratio of -9.89 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The business had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Wedbush upped their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. The Goldman Sachs Group assumed coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Finally, Chardan Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new stake in Stoke Therapeutics during the 4th quarter worth approximately $26,000. Quantbot Technologies LP acquired a new position in shares of Stoke Therapeutics in the second quarter worth $34,000. KBC Group NV acquired a new position in shares of Stoke Therapeutics in the first quarter worth $36,000. Harbour Investments Inc. increased its position in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.